Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Indomethacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 9/20 | 0.96 |
| ▸ | PTGS1 known ✓ | P23219 | 4/20 | 0.96 |
| ▸ | AKR1C3 | P42330 | 7/20 | 0.96 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.96 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.96 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.96 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.96 |
| ▸ | LMNA | P02545 | 2/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.96 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.96 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.96 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.96 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.96 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.96 |
| ▸ | MEN1 | O00255 | 1/20 | 0.96 |
| ▸ | PTGES | O14684 | 1/20 | 0.96 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.96 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.96 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indomethacin SCHEMBL42049 | 0.99 | PTGS2 (0.98) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL22472310 | 0.99 | PTGS2 (0.98) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL6554617 | 0.99 | PTGS2 (0.98) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL473598 | 0.99 | PTGS2 (0.98) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL11441233 | 0.98 | PTGS2 (0.96) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL6556597 | 0.98 | PTGS2 (0.96) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL29353712 | 0.98 | PTGS2 (1.00) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL29525957 | 0.98 | PTGS2 (1.00) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL9300 | 0.98 | PTGS2 (1.00) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL3518614 | 0.98 | PTGS2 (1.00) | PTGS2AKR1C3AKR1C2PTGS1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 976 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250256009-A1 | DECELLULARIZED BIOMATERIAL FROM NON-MAMMALIAN TISSUE | NEXTGEN BIOLOGICS, INC. (US) | 2025-08-14 | — | — | US | claimed |
| EP-2111185-B1 | BIOERODIBLE WRAPS AND USES THEREFOR | UNIV OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-12-20 | — | — | EP | claimed |
| US-20160317280-A1 | Bioerodible Wraps and Uses Therefor | THE UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2016-11-03 | — | — | US | claimed |
| US-9237945-B2 | Bioerodible wraps and uses therefor | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2016-01-19 | — | — | US | claimed |
| US-20130011470-A1 | PHARMACEUTICAL FORMULATIONS OF NAPROXEN FOR SOFT GEL ENCAPSULATION AND COMBINATIONS THEREOF | ACCUCAPS INDUSTRIES LIMITED (CA) | 2013-01-10 | — | — | US | claimed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | claimed |
| WO-2011088553-A1 | PHARMACEUTICAL FORMULATIONS OF NAPROXEN FOR SOFT GEL ENCAPSULATION AND COMBINATIONS THEREOF | ACCUCAPS INDUSTRIES LIMITED (CA) | 2011-07-28 | — | — | WO | claimed |
| JP-2010516437-A | — | — | 2010-05-20 | — | — | JP | claimed |
| EP-2111185-A2 | BIOERODIBLE WRAPS AND USES THEREFOR | University of Pittsburgh of the Commonwealth System of Higher Education (US) | 2009-10-28 | — | — | EP | claimed |
| US-20080208323-A1 | Bioerodible wraps and uses therefor | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-08-28 | — | — | US | claimed |
| US-20050180951-A1 | Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer | OHNO TSUNEYA (US) | 2005-08-18 | — | — | US | claimed |
| US-20040028663-A1 | Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer | OHNO TSUNEYA (US) | 2004-02-12 | — | — | US | claimed |
| US-4968507-A | SUSTAINED RELEASE OF DRUG | MERCK & CO., INC. (US) | 1990-11-06 | — | — | US | claimed |
| US-4851228-A | Multiparticulate controlled porosity osmotic | MERCK & CO., INC. (US) | 1989-07-25 | — | — | US | claimed |
| EP-0137364-A2 | Suppository form of an osmotic therapeutic system | MERCK & CO. INC. (US) | 1985-04-17 | — | — | EP | claimed |
| EP-0040899-B1 | METHOD OF DELIVERING DRUG WITH AID OF EFFERVESCENT ACTIVITY GENERATED IN ENVIRONMENT OF USE | ALZA CORPORATION (US) | 1984-09-12 | — | — | EP | claimed |
| US-4344929-A | Method of delivering drug with aid of effervescent activity generated in environment of use | ALZA CORPORATION (US) | 1982-08-17 | — | — | US | claimed |
| EP-0040899-A2 | Method of delivering drug with aid of effervescent activity generated in environment of use | ALZA CORPORATION (US) | 1981-12-02 | — | — | EP | claimed |
| US-4265874-A | Method of delivering drug with aid of effervescent activity generated in environment of use | ALZA CORPORATION (US) | 1981-05-05 | — | — | US | claimed |
| US-4256108-A | Microporous-semipermeable laminated osmotic system | ALZA CORPORATION (US) | 1981-03-17 | — | — | US | claimed |